New Treatment Approved by FDA for Lysosomal Acid Lipase Deficiency

The Food and Drug Administration (FDA) approved a drug called sebelipase alfa (Kanuma) as the first-ever treatment for lysosomal acid lipase deficiency (LAL)—a rare inherited disorder. LAL deficiency causes a build-up of fats within the cells of various tissues that can lead to liver and cardiovascular diseases and other complications.

Read more

Should Patients with Crohn’s Disease Continue Receiving Immunomodulators When Starting Anti-TNF Therapy?

Continued use of immunomodulator therapy in patients with Crohn’s disease receiving anti-tumor necrosis factor (TNF) therapy is no more effective than anti-TNF monotherapy in inducing or maintaining response or remission, researchers show. The meta-analysis of randomized controlled trials is published in the December issue of Clinical Gastroenterology and Hepatology. There is debate

Read more
  • Medicaid Denies Almost 50% of Prescriptions for Hepatitis C Drugs in 4 States

Medicaid Denies Almost 50% of Prescriptions for Hepatitis C Drugs in 4 States

Medicaid programs in Delaware, Maryland, New Jersey, and Pennsylvania denied nearly half of all claims in the past year for direct-acting antiviral (DAA) hepatitis C drugs, according to an analysis of pharmacy data presented at the American Association for the Study of Liver Diseases 2015 Liver Meeting. The finding confirms

Read more
  • Gut Microbiome Determines Efficacy of Cancer Immunotherapy

Gut Microbiome Determines Efficacy of Cancer Immunotherapy

Specific groups of intestinal microbes can boost the anti-tumor effects of cancer immunotherapies in mice, researchers show. Cancer immunotherapies that block immune inhibitory pathways have been tested in patients with several tumor types, but responses have varied. A study published in Science, while not the first to link gut microbes

Read more

Obesity Appears to Contribute to Increasing Use of Prescription Drugs

Prescription drug use in the United States increased by 8% over a 10 year period, and users of 5 or more prescription drugs almost doubled. Increases in prescriptions for specific agents appears to reflect the growing need for treatment of complications associated with the increase in overweight and obesity. The

Read more
  • Special Issue: Managing Patients With Liver Disease

Special Issue: Managing Patients With Liver Disease

A special issue of Clinical Gastroenterology and Hepatology is dedicated to the clinical management of hepatic disorders, including nonalcoholic fatty liver disease (NAFLD), viral hepatitis, autoimmune hepatitis, and primary sclerosing cholangitis (PSC). The issue comprises 14 review articles that aim to present clinicians with evidence-based guidance and expert opinions on management of patients with liver

Read more
  • This is Your Brain on Anti-TNF Therapy

This is Your Brain on Anti-TNF Therapy

Anti-tumor necrosis factor (anti-TNF) agents rapidly reduce pain perception in brains of patients with Crohn’s disease, researchers show in the October issue of Gastroenterology. This observation could explain how clinical disease activity is often reduced long before signs of mucosal healing. Patients with Crohn’s disease treated with anti-TNF agents often report reductions in abdominal pain

Read more
  • A Non-Antibiotic Against Clostridium difficile Infection

A Non-Antibiotic Against Clostridium difficile Infection

A non-antibiotic drug reduces the effects Clostridium difficile infection (CDI) by disabling the bacteria’s toxins, a study showed in mice. The orally administered agent, ebselen, has been in clinical trials for an unrelated condition and could offer a new approach for combating multidrug-resistant CDI. C difficile infection causes life-threatening diarrhea and

Read more
  • Expert Panel Recommends Aspirin Therapy for Prevention of Colorectal Cancer

Expert Panel Recommends Aspirin Therapy for Prevention of Colorectal Cancer

For the first time, an expert panel has recommended aspirin therapy to prevent not only heart attacks but also colorectal cancer. The guideline for those at high risk of heart disease, published September 14 in a draft report from the US Preventive Services Task Force is the first time a major

Read more
  • Poor Adherence to Guidelines in Many Cases of Isoniazid-induced Liver Injury

Poor Adherence to Guidelines in Many Cases of Isoniazid-induced Liver Injury

Isoniazid is used to treat tuberculosis but is also a leading cause of liver injury. However, it is not clear how many cases of isoniazid-associated liver injury are reported or how many clinicians and patients adhere to American Thoracic Society (ATS) guidelines. In the September issue of Clinical Gastroenterology and Hepatology,

Read more